Imre (US) begins Prosorba trial for kidney transplantation:
This article was originally published in Clinica
Imre (US) has begun a clinical trial to evaluate the Prosorba column as a means to increase the number of patients eligible for kidney transplantation. The 15-patient study, to be carried out at the Cleveland Clinic, will determine if the Prosorba column reduces the level of sensitising antibodies which cause acute organ rejection. Imre estimates around a quarter of patients awaiting kidney transplantation are ineligible because they have developed alloantibodies to a variety of donor tissues.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.